TITLE

HOLLIS-EDEN GETS EUROPEAN PATENT RIGHTS FOR RADIATION DRUG

PUB. DATE
February 2003
SOURCE
Worldwide Biotech;Feb2003, Vol. 15 Issue 2, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the notice received by Hollis-Eden Pharmaceuticals Inc. from the European Patent Office concerning the issue of claims that cover the leading anti-radiation and chemotherapy protection drug candidates of the company.
ACCESSION #
9014630

 

Related Articles

  • Biopharmaceutical firm licenses patents to San Diego company.  // Enterprise/Salt Lake City;9/2/2002, Vol. 32 Issue 9, p18 

    Reports on the patent licensing agreement between Pharmadigm Inc. and Hollis-Eden Pharmaceuticals Inc. in the U.S. Terms of the agreement; Research in the fields of inflammation and immunology.

  • HOLLIS-EDEN REPORTS HE2500 REDUCES PARALYSIS FROM EAE.  // Biotech Business;Jun2002, Vol. 15 Issue 6, p4 

    Reveals that a preclinical study conducted by Hollis-Eden Pharmaceuticals Inc. has demostrated that HE2500, an investigational immune regulating hormone, reduces ongoing paralysis and accelerates recovery from experimental autoimmune encephalomyelitis.

  • Hollis-Eden Changes Name: Now Harbor BioSciences. Chambers, Heather // San Diego Business Journal;2/22/2010, Vol. 31 Issue 8, p5 

    The article reports on the move of Hollis-Eden Pharmaceuticals Inc. to change its name to assume Harbor BioSciences Inc. effective February 18, 2010.

  • Hollis-Eden Pharmaceuticals Inc.  // San Diego Business Journal;11/22/99, Vol. 20 Issue 47, p29 

    Discloses information about Hollis-Eden Pharmaceuticals Inc. Stock market value as of November 15, 1999; Performance record; Board of directors; Executive compensation; Significant stock ownership.

  • Hollis-Eden Starts Immune Response Trials for Elderly.  // San Diego Business Journal;4/15/2002, Vol. 23 Issue 15, p6 

    Reports the start of safety trial to find experimental drug to stimulate immune response among elderly patients following hepatitis B vaccinations by Hollis-Eden Pharmaceuticals Inc. in San Diego, California.

  • Hollis-Eden Pushes for Update to BioShield. Weeks, Katie // San Diego Business Journal;4/17/2006, Vol. 27 Issue 16, p1 

    The article reports on the emphasis by bio-defense company Hollis-Eden Pharmaceuticals Inc. at a gathering of biotech companies to revamp its Project BioShield in Chicago, Illinois. The project is testing the drug Neumune for saving lives following a nuclear attack. Hollis-Eden has submitted two...

  • Firm Trumpets Results of Experimental Malaria Drug. Webb, Marion // San Diego Business Journal;11/19/2001, Vol. 22 Issue 47, p10 

    Reports the development of a malarial drug by Hollis-Eden Pharmaceuticals Inc. Presentation of the drug during the American Society of Tropical Medicine and Hygiene conference; Effects of the experimental drug, HE2000; Discussion about malaria.

  • Experimental Therapy on Path for Phase II Testing.  // San Diego Business Journal;12/3/2001, Vol. 22 Issue 49, p13 

    Reports on the safe use of an experimental therapy in helping individuals by Hollis-Eden Pharmaceuticals, Inc. in San Diego, California.

  • AIDS Vaccine Researchers Report Having Initial Success. Webb, Marion // San Diego Business Journal;07/17/2000, Vol. 21 Issue 29, p8 

    Reports that San Diego, California-based biotechnology firms Immune Response Corp. and Hollis-Eden Pharmaceuticals Inc. are developing vaccines designed to restore the damaged immune systems of HIV-infected patients. Presentation of study results at the July 2000 International AIDS Conference...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics